SCHEMBL3918182

SCHEMBL3918182

COC(=O)c1ccc(CN2C(=O)C(C(C)C)NC23CCN(C(=O)Nc2cccc(OC)c2)CC3)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
HTT P42858 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
FAAH O00519 3/20 0.46
OPRM1 P35372 1/20 0.45
OPRD1 P41143 1/20 0.45
OPRK1 P41145 1/20 0.45
CCR3 P51677 4/20 0.44
ALDH1A1 P00352 5/20 0.44
MAPT P10636 3/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
LMNA P02545 3/20 0.43
TP53 P04637 1/20 0.43
GRIN2B Q13224 1/20 0.42
TSHR P16473 2/20 0.42
MAPK1 P28482 2/20 0.42
USP2 O75604 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3919278 0.83 SLC6A3 (0.44) FAAHMAPTGRIN2B
SCHEMBL3918951 0.80 LMNA (0.44) HTTNPC1RAB9AALDH1A1MAPT
SCHEMBL3928978 0.80 LMNA (0.41) SMN1; SMN2HTTNPC1RAB9AALDH1A1
SCHEMBL3915520 0.79 HRH3 (0.48) SMN1; SMN2HTTNPC1RAB9AMEN1
SCHEMBL1799198 0.79 LMNA (0.39) SMN1; SMN2HTTNPC1RAB9AOPRD1
SCHEMBL3914913 0.78 GAA (0.41) SMN1; SMN2HTTNPC1RAB9AALDH1A1
SCHEMBL3916498 0.76 GAA (0.44) SMN1; SMN2HTTNPC1RAB9AFAAH
SCHEMBL1799799 0.76 CYP2C19 (0.41) SMN1; SMN2HTTNPC1RAB9AOPRD1
SCHEMBL3916428 0.75 KDM4E (0.42) HTTNPC1RAB9AOPRD1OPRK1
SCHEMBL3926266 0.75 MAPT (0.47) SMN1; SMN2HTTNPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US claimed
EP-1730144-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5 DECAN-2-ONE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-06-10 EP claimed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US disclosed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds THPO, UGT1A8, UGT1A4 SMN1; SMN2 1274/4885HTT 509/4885NPC1 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.